The One Health Antimicrobial Resistance partnership (OH AMR) has been identified by the European Commission as one of the European Partnerships of Horizon Europe. Currently, the Research and Innovation Objectives of OH AMR are under preparation, and we now invite researchers, stakeholders, scientists, policymakers, clinicians, patient groups, AMR-related organisations, and others to provide feedback on the elements included in the Research and Innovations Objectives.
Please activate the online survey for this purpose here: Survey: OH AMR Research and Innovation Objectives
The consultation is open until 16 January 2023.
The online consultation outcome will guide the development of the final Research and Innovations Objectives, which will be included in the OH AMR Strategic Research and Innovation Agenda.
The Research and Innovation Objectives have been developed through a number of consultations during 2022. The latest version of the document can be found here: Research and Innovation Objectives of the OH AMR Partnership (pdf, 1 MB)
For questions regarding the consultation, please contact email@example.com.
About the OH AMR Partnership
In the research framework of Horizon Europe and collaboration with the member states, the European Commission has identified 49 new European Partnerships, one of which is the “One Health Antimicrobial Resistance Partnership.”
The future One Health AMR (OH AMR) Partnership will be a joint research program co-funded by the European Commission and EU member states. The OH AMR Partnership aims to coordinate and align AMR activities and funding between countries and the European level. With a mix of EU and national public R&I funding, the OH AMR partnership will develop joint calls and activities to address the objectives of the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR to reduce the burden of AMR.
For more information about the OH AMR Partnership, visit www.ohamr.eu.